UK regulator approves orforglipron tablet for weight and diabetes
The MHRA authorised orforglipron (Foundayo) on 10 August 2026, the first European approval of an oral GLP-1 tablet for weight management and type 2 diabetes. It is authorised for adults with specified BMI thresholds and for glycaemic control in insufficiently controlled type 2 diabetes. The tablet is once daily with no food restrictions and dose escalation begins at 0.8 mg up to 17.2 mg with at least one month per dose step. Common side effects include nausea, constipation and diarrhoea. The medicine is prescription only, not yet available via the NHS, and will face NICE evaluation and ongoing MHRA monitoring.
MHRA authorised an oral GLP-1 tablet for obesity and type 2 diabetes.
Context
The MHRA has authorised orforglipron as a new oral GLP-1 medicine. Next, NICE will evaluate NHS use and the MHRA will monitor safety. Other regulators may consider similar decisions later.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked